Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
Capricor Therapeutics' (CAPR) "Buy" Rating Reiterated at Maxim Group
09:40am, Tuesday, 24'th Mar 2020
Maxim Group reiterated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a report released on Friday morning, AnalystRatings.com reports. Maxim Group currently has a $4.00 target pr
Capricor Therapeutics (CAPR) Gets a Buy Rating from Maxim Group
02:14pm, Friday, 20'th Mar 2020
Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR) today and set a price target of $4.00. The company's shares
Capricor Therapeutics (CAPR) Gets a Buy Rating from Maxim Group
02:14pm, Friday, 20'th Mar 2020
Maxim Group analyst
Jason McCarthy
maintained a
Buy
rating on Capricor Therapeutics (
CAPR
–
Research Report
) today and set a price target of
$4.00
. The company’s shares closed last Monday at $1
4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis
12:30pm, Thursday, 19'th Mar 2020
Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.
4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis
12:30pm, Thursday, 19'th Mar 2020
Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.
Analysts Offer Insights on Healthcare Companies: Vaxart (VXRT), Enlivex Therapeutics (ENLV) and Capricor Therapeutics (CAPR)
11:10am, Thursday, 19'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vaxart (VXRT), Enlivex Therapeutics (ENLV) and Capricor
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vaxart (
VXRT
–
Research Report
), Enlivex Therapeutics (
ENLV
–
Research Report
) and Capricor The
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
12:00am, Thursday, 19'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
7 Stocks Moving In Wednesday's After-Hours Session
09:05pm, Wednesday, 18'th Mar 2020
Gainers
Five Below (NASDAQ: FIVE) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.
Capricor Therapeutics (NASDAQ...
Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
08:01pm, Wednesday, 18'th Mar 2020
-To Report Final 12-month HOPE-2 Data in the Second Quarter- -Exosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus- -To Host Conference Call and.
Capricor Therapeutics, Inc. to Host Earnings Call
06:30pm, Wednesday, 18'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 18, 2020 / Capricor Therapeutics, Inc. (NASDAQ:CAPR) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 18, 2020
SLS, APRN among premarket gainers
01:23pm, Wednesday, 18'th Mar 2020
Biomerica (NASDAQ:BMRA) +133% on advancement of rapid coronavirus test.IMV (NASDAQ:IMV) +55% on coronavirus vaccine plan.Vaxart (NASDAQ:VXRT) +46% on coronavirus vaccine deal.Blue Apron Holdings (N
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
11:36am, Wednesday, 18'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron P
Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion
12:00pm, Tuesday, 17'th Mar 2020
Capricor Therapeutics (CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and othe
The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review
01:55pm, Sunday, 15'th Mar 2020
The biopharma space bled along with the rest of the market and COVID-19 levered biotechs weren't spared either.Biogen Inc (NASDAQ: BIIB) was in the news for all wrong reasons, as an employee conferenc
